Insights

Gone are the days when a single, widely prescribed drug could sustain a company’s growth and profitability for years. Today, […]

India’s pharmaceutical sector stands as a beacon of both immense potential and significant challenges. As the world’s largest provider of

Personalized medicine tailors medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. However, as with any

This article was originally published by Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, and Aaron S Kesselheim

Officially known as Approved Drug Products With Therapeutic Equivalence Evaluations, the FDA Orange Book contains a list of drugs considered

While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts

Combination products have emerged as a fascinating frontier, blending the realms of pharmaceuticals, medical devices, and biotechnology. These hybrid creations

By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain